The US Food and Drug Administration has approved a new recombinant product for the treatment of Haemophilia A, an inherited, sex-linked blood clotting disorder that is caused by defects in the Factor VIII gene. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
